Hepatic cytochrome P450 2E1 activity in nonalcoholic fatty liver disease

Journal of the Medical Association of Thailand

Volumn 91, Issue 5, 2008, Pages 733-738

  Prompila, Nantaporn ^a   Wittayalertpanya, Supeecha ^a   Komolmit, Piyawat ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Chlorzoxazone; CYP2E1; Nonalcoholic fatty liver disease

Indexed keywords

6 HYDROXYCHLORZOXAZONE; CHLORZOXAZONE; CYTOCHROME P450 2E1; LIVER ENZYME; MASELAX;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CHRONOLOGY; CLINICAL ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DRUG BLOOD LEVEL; ENZYME ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAXIMUM PLASMA CONCENTRATION; NONALCOHOLIC FATTY LIVER; TIME TO MAXIMUM PLASMA CONCENTRATION; ULTRAVIOLET RADIATION;

ADULT; CASE-CONTROL STUDIES; CHLORZOXAZONE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP2E1; FATTY LIVER; FEMALE; HUMANS; LIPID PEROXIDATION; LIVER; MALE; MUSCLE RELAXANTS, CENTRAL; OXIDATIVE STRESS; PILOT PROJECTS;

EID: 44649126118     PISSN: 01252208     EISSN: 01252208     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Grant LM, Lisker-Melman M. Nonalcoholic fatty liver disease. Ann Hepatol 2004; 3: 93-9.
2. Yu AS, Keeffe EB. Nonalcoholic fatty liver disease. Rev Gastroenterol Disord 2002; 2: 11-9.
3. Harrison SA, Kadakia S, Lang KA, Schenker S. Nonalcoholic steatohepatitis: what we know in the new millennium. Am J Gastroenterol 2002; 97: 2714-24.
4. Collantes R, Ong JP, Younossi ZM. Nonalcoholic fatty liver disease and the epidemic of obesity. Cleve Clin J Med 2004; 71: 657-64.
5. Chalasani N, Gorski JC, Asghar MS, Asghar A, Foresman B, Hall SD, et al. Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. Hepatology 2003; 37: 544-50.
6. Weltman MD, Farrell GC, Hall P, Ingelman-Sundberg M, Liddle C. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 1998; 27: 128-33.
7. Emery MG, Fisher JM, Chien JY, Kharasch ED, Dellinger EP, Kowdley KV, et al. CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease. Hepatology 2003; 38: 428-35.
8. Weltman MD, Farrell GC, Liddle C. Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology 1996; 111: 1645-53.
9. Kramer I, Dalhoff K, Clemmesen JO, Loft S, Poulsen HE. Comparison of chlorzoxazone one-sample methods to estimate CYP2E1 activity in humans. Eur J Clin Pharmacol 2003; 59: 775-8.
10. Frye RF, Stiff DD. Determination of chlorzoxazone and 6-hydroxychlorzoxazone in human plasma and urine by high-performance liquid chromatography. J Chromatogr B Biomed Appl 1996; 686: 291-6.
11. Dreisbach AW, Ferencz N, Hopkins NE, Fuentes MG, Rege AB, George WJ, et al. Urinary excretion of 6-hydroxychlorzoxazone as an index of CYP2E1 activity. Clin Pharmacol Ther 1995; 58: 498-505.
12. U.S. Department of Health and Human Services, Food and Drug Administration. Guidance for industry: bioanalytical method validation. Rockville, MD: U.S. Department of Health and Human Services, FDA, Center for Drug Evaluation and Research; 2001.
13. Mishin VM, Rosman AS, Basu P, Kessova I, Oneta CM, Lieber CS. Chlorzoxazone pharmacokinetics as a marker of hepatic cytochrome P4502E1 in humans. Am J Gastroenterol 1998; 93: 2154-61.
14. Nolin TD, Gastonguay MR, Bies RR, Matzke GR, Frye RF. Impaired 6-hydroxychlorzoxazone elimination in patients with kidney disease: Implication for cytochrome P450 2E1 pharmacogenetic studies. Clin Pharmacol Ther 2003; 74: 555-68.
15. Lucas D, Berthou F, Girre C, Poitrenaud F, Menez JF. High-performance liquid chromatographic determination of chlorzoxazone and 6-hydroxy- chlorzoxazone in serum: a tool for indirect evaluation of cytochrome P4502E1 activity in humans. J Chromatogr 1993; 622: 79-86.